Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-17T16:45:29.781Z Has data issue: false hasContentIssue false

Chapter 1 - A Brief History of Psychopharmacology

from Part 1 - Basic Science and General Principles

Published online by Cambridge University Press:  29 May 2020

By
Peter M. Haddad ,
David J. Nutt  and
A. Richard Green
Edited by
Peter M. Haddad  and
David J. Nutt
Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access

Summary

The Oxford English Dictionary defines psychopharmacology as ‘the scientific study of the effect of drugs on the mind and behaviour’ (Oxford English Dictionary Online, 2018). The earliest reference to the term was in 1548 when Reinhard Lorichius published the prayer book Psychopharmakon, hoc est Medicina Animae (Lehmann, 1993; Wolman, 1977). Lorichius coined the term ‘psychopharmakon’ to refer to spiritual medicine that could reduce human suffering. The word psychopharmacology was first used in a scientific paper in 1920 by a pharmacologist working at Johns Hopkins University who wrote a short paper entitled Contributions to psychopharmacology (Macht, 1920).

Type
Chapter
Information
Seminars in Clinical Psychopharmacology , pp. 1 - 34
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ackner, B, Harris, A, Oldham, AJ (1957). Insulin treatment of schizophrenia; a controlled study. Lancet, ii, 607–611.Google Scholar
Adams, CP, Brantner, VV (2010). Spending on new drug development. Health Econ, 19, 130–141.Google Scholar
Adelson, D, Epstein, LJ (1962). A study of phenothiazines with male and female chronically ill schizophrenic patients. J Nerv Ment Dis, 134, 543–554.CrossRefGoogle ScholarPubMed
Akers, BP, Ruiz, JF, Piper, A, Ruck, CAP (2011). A prehistoric mural in Spain depicting neurotropic psilocybe mushrooms? Econ Bot, 65, 121–128.CrossRefGoogle Scholar
Amin, AH, Crawford, TBB, Gaddum, JH (1954). The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. J Physiol, 125, 596–618.Google Scholar
Angst, J, Weis, P, Grof, P, et al. (1970). Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry, 116, 604–614.Google Scholar
Baastrup, PC, Schou, M (1967). Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry, 16, 162–172.Google Scholar
Baastrup, PC, Poulsen, JC, Schou, M, et al. (1970). Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet, 2, 326–330.CrossRefGoogle ScholarPubMed
Ban, TA, Ray, OS (1996). A History of the CINP. Brentwood TN: JM Productions, pp. 457.Google Scholar
Björklund, A, Dunnett, SB (2007). Fifty years of dopamine research. Trends Neurosci, 30, 185–187.Google Scholar
Blackwell, B (1963). Hypertensive crises due to monoamine inhibitors. Lancet, ii, 849–851.Google Scholar
Board of Control for England and Wales (1947). Prefrontal Leucotomy in 1,000 Cases. London: HMSO.Google Scholar
Bowen, DM, Smith, CB, White, P, Davison, AN (1976). Neurotransmitter-related enzymes and indices of hypoxia in senile demementia and other abiotrophies. Biochem J, 99, 459–496.Google ScholarPubMed
Bradley, C (1937). The behavior of children receiving benzedrine. Am J Psychiatry, 94, 577–581.CrossRefGoogle Scholar
Bradley, C, Bowen, M (1940). Amphetamine (Benzedrine) therapy of children’s behavior disorders. Am J Orthopsychiatry, 11, 92–103.CrossRefGoogle Scholar
Braestrup, C, Squires, RF (1977). Stereospecific benzodiazepine receptors in rat brain characterized by high affinity (3H)-diazepam binding. Proc Natl Acad Sci USA, 74, 3805–3809.Google Scholar
Brown, WA, Rosdolsky, M (2015). The clinical discovery of imipramine. Am J Psychiatry, 172, 426–429.CrossRefGoogle ScholarPubMed
Cade, JFJ (1949). Lithium salts in the treatment of psychotic excitement. Med J Aust, 2, 349–352.Google Scholar
Carhart-Harris, RL, Nutt, DJ (2017). Serotonin and brain function: a tale of two receptors. J Psychopharmacol, 31, 1091–1120.Google Scholar
Carhart-Harris, RL, Bolstridge, M, Rucker, J, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7), 619–627.Google Scholar
Carlsson, A, Lindqvist, M (1963). Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine on mouse brain. Acta Pharmacol Toxicol, 20, 140–144.Google Scholar
Casey, JF, Bennett, IF, Lindley, CJ, et al. (1960). Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. AMA Arch Gen Psychiatry, 2, 210–220.Google Scholar
Cleare, A, Pariante, CM, Young, AH, et al. (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol, 29, 459–525.Google Scholar
Committee on Safety of Medicines (1986). CSM Update: withdrawal of nomifensine. Br Med J (Clin Res Ed), 293, 41.Google Scholar
Coppen, A (1967). The biochemistry of affective disorders. Br J Psychiatry, 113, 1237–1264.Google Scholar
Coppen, A, Shaw, DM, Farrell, JP (1963). Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet, 281, 79–81.CrossRefGoogle Scholar
Cowen, PJ (2008). Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci, 29, 433–436.Google Scholar
Crismon, ML (1994). Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother, 28, 744–751.CrossRefGoogle ScholarPubMed
Cryan, JF, Sweeney, FF (2011). The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol, 164, 1129–1161.Google Scholar
Cummings, J, Lee, G, Ritter, A, Zhong, K (2018). Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement (N Y), 4, 195–214.CrossRefGoogle Scholar
Delay, J, Deniker, P, Harl, JM (1952). Utilisation en thérapeutique d’une phénothiazine d’action centrale selective. Ann Med Psychol (Paris), 110, 112–117.Google Scholar
Dos Santos, RG, Bouso, JC, Alcázar-Córcoles, MÁ, Hallak, JEC (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol, 11(9), 889–902.CrossRefGoogle ScholarPubMed
El-Seedi, HR, De Smet, PA, Beck, O, Possnert, G, Bruhn, JG (2005). Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol, 101, 238–242.Google Scholar
Enna, SJ, Williams, M (2009). Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther, 329, 404–411.CrossRefGoogle ScholarPubMed
Enna, SJ, Bennett, JP Jr, Burt, DR, Creese, I, Snyder, SH (1976). Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature, 263, 338–341.Google Scholar
European Medicines Agency (2012). Questions and answers on the suspension of the marketing authorisations for oral meprobamate containing medicines. Available at: www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/meprobamate_107/WC500120737.pdf (last accessed 29.4.18).Google Scholar
Fagius, J, Osterman, PO, Sidén, A, Wiholm, BE (1985). Guillain-Barré syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry, 48(1), 65–69.CrossRefGoogle ScholarPubMed
Farzampour, Z, Reimer, RJ, Huguenard, J (2015). Endozepines. Adv Pharmacol, 72, 147–164.CrossRefGoogle ScholarPubMed
Fava, M, Memisoglu, A, Thase, ME, et al. (2016). Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry, 173, 499–508.Google Scholar
Fineberg, NA, Haddad, PM, Carpernter, L, et al. (2013). The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol, 27, 761–770.Google Scholar
Francis, PT (2009). Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol, 2, 77–82.Google Scholar
Frankel, JS, Schwartz, TL (2017). Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol, 7(1), 29–41.CrossRefGoogle ScholarPubMed
Gaddum, JH (1954). Discoveries in therapeutics. J Pharm Pharmacol, 6, 497–512.Google Scholar
Garay, RP, Citrome, L, Samalin, L, et al. (2016). Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother, 17(7), 921–936.Google Scholar
Garay, RP, Zarate, CA Jr, Charpeaud, T, et al. (2017). Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother, 17(6), 593–609.Google Scholar
Goodwin, GM, DeSouza, RJ, Green, AR (1985). Presynaptic serotonin-mediated response in mice attenuated by antidepressants and electroconvulsive shock. Nature, 317, 531–533.Google Scholar
Goodwin, GM, Haddad, PM, Ferrier, IN, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30, 495–553.Google Scholar
Gøtzsche, PC, Young, AH, Crace, J (2015). Maudsley Debate. Does long term use of psychiatric drugs cause more harm than good? BMJ, 350, h2435.CrossRefGoogle Scholar
Grahame-Smith, DG (1997). ‘Keep on taking the tablets’: pharmacological adaptation during long-term drug therapy. Br J Clin Pharmacol, 44, 227–238.Google Scholar
Grahame-Smith, DG, Aronson, JK (1992). Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford: Oxford University Press.Google Scholar
Green, AR, Aronson, JK (2012). From basic to clinical neuropharmacology: targetophilia or pharmacodynamics. Br J Clin Pharmacol, 73, 959–967.CrossRefGoogle ScholarPubMed
Green, AR, Haddad, PM (2016). The British Association for Psychopharmacology: The First 40 Years. Cambridge: British Association for Psychopharmacology.Google Scholar
Green, AR, Marsden, CA (2013). How do we re-engage the pharmaceutical industry in research on serotonin and psychiatric disorders? ACS Chem Neurol, 4, 9–12.Google Scholar
Green, AR, Aronson, JK, Haddad, PM (2018a). Examining the ‘psychopharmacology revolution’ (1950–1980) through the advertising of psychoactive drugs in the British Medical Journal. J Psychopharmacol, 32, 1056–1066.CrossRefGoogle ScholarPubMed
Green, AR, Haddad, PM, Aronson, JK (2018b). Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950–1980). Br J Clin Pharmacol, 84, 1668–1685.Google Scholar
Griesinger, W (1861). Pathologie und Therapie der psychischen Krankheiten (Mental Pathology and Therapeutics), Stuttgart: Krabbe, 1845; second edition, Braunschweig, 1861.Translated by C Lockhart Robertson and James Rutherford, New York: William Wood and Company, 1882. Available at: https://archive.org/stream/mentalpathology00ruthgoog#page/n6/mode/2up (last accessed 2.8.19).Google Scholar
Grob, GG (1991). From Asylum to Community Mental Health Policy in Modern America. Princeton, NJ: Princeton University Press.CrossRefGoogle Scholar
Gronfein, W (1985). Incentives and intentions in mental health policy: a comparison of the Medicaid and community mental health programs. J Health Soc Behav, 26, 192–206.Google Scholar
Hamon, J, Paraire, J, Velluz, J (1952). Remarques sur l’action du 4560 RP sur l’agitation maniaque. Ann Med Psychol (Paris), 110, 331–335.Google Scholar
Himwich, HE (1958). Psychopharmacologic drugs. Science, 127, 59–72.Google Scholar
Hippius, H (1999). A historical perspective of clozapine. J Clin Psychiatry, 60(Suppl 12), 22–23.Google ScholarPubMed
Holden, TJ, Cavanagh, WG (1987). Use of paraldehyde. Br J Psychiatry, 150, 564–565.Google Scholar
Horrobin, DF (2003). Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov, 2, 151–154.CrossRefGoogle ScholarPubMed
Howes, OD, Kapur, S (2009). The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull, 35, 549–562.Google Scholar
Hutton, EL, Fleming, GWTH, Fox, EE (1941). Early results of prefrontal leucotomy. Lancet, ii, 3–7.Google Scholar
Idanpaan-Heikkila, J, Alhava, E, Olkimora, M, Palva, J (1975). Clozapine and agranulocytosis. Lancet, 2, 611.Google Scholar
Iversen, LL (1971). Role of transmitter uptake systems in synaptic neurotransmission. Br J Pharmacol, 41, 571–591.CrossRefGoogle ScholarPubMed
Janssen (2019). SPRAVATO (esketamine) nasal spray, CII Prescribing information. Available at: www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf (last accessed 25.5.19).Google Scholar
Johnson, DAW (2009). Historical perspective on antipsychotic long-acting injections. Br J Psychiatry, 195, S7–S12.CrossRefGoogle Scholar
Jones, BJ, Blackburn, TP (2002). The medical benefit of 5-HT research. Pharmacol Biochem Behav, 71, 555–568.Google Scholar
Jones, CA, Watson, DJG, Fone, KCF (2011). Animal models of schizophrenia. Br J Pharmacol, 164, 1162–1194.CrossRefGoogle ScholarPubMed
Jones, CW, Handler, L, Crowell, KE, et al. (2013). Non-publication of large randomized clinical trials: cross sectional analysis. BMJ, 347, f6104.Google Scholar
Jones, K (2000). Insulin coma therapy in schizophrenia. J R Soc Med, 93, 147–149.CrossRefGoogle ScholarPubMed
Jones, PB, Barnes, TR, Davies, L, et al. (2006). Randomized controlled trial of effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 63, 1079–1087.Google Scholar
Kane, J, Honigfield, G, Singer, J, et al. (1988). Clozapine for the treatment-resistant schizophrenic; a double-blind comparison with chlorpromazine (Clozaril Collaborative Study). Arch Gen Psychiatry, 45, 789–796.Google Scholar
Kern, RS, Nuechterlein, KH, Green, MF, et al. (2008). The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry, 165, 214–220.Google Scholar
Kishimoto, T, Agarwal, V, Kishi, T, et al. (2013a). Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry, 18, 53–66.Google Scholar
Kishimoto, T, Nitta, M, Borenstein, M, Kane, JM, Correll, CU (2013b). Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry, 74, 957–965.Google Scholar
Kishimoto, T, Robenzadeh, A, Leucht, C, et al. (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull, 40, 192–213.Google Scholar
Kishimoto, T, Hagi, K, Nitta, M, et al. (2018). Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull, 44, 603–619.CrossRefGoogle ScholarPubMed
Kuhn, R. (1958). The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry, 115, 459–464.Google Scholar
Lader, M (2014). Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol, 77, 295–301.Google Scholar
Lamb, HR, Bachrach, LL (2001). Some perspectives on deinstitutionalization. Psychiatr Serv, 52, 1039–1045.CrossRefGoogle ScholarPubMed
Lange, KW, Reichl, S, Lange, KM, et al. (2010). The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord, 2, 241–255.Google Scholar
Lehmann, HE (1993). Before they called it psychopharmacology. Neuropsychopharmacology, 8, 291–303.Google Scholar
Leucht, S, Tardy, M, Komossa, K, et al. (2012). Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev,(5), CD008016.Google Scholar
Leucht, S, Cipriani, A, Spineli, L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382, 951–962.Google Scholar
Lewis, SW, Barnes, TR, Davies, L, et al. (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull, 32(4), 715–723.Google Scholar
Li, ML, Hu, XQ, Li, F, Gao, WJ (2015). Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end? Prog Neuropsychopharmacol Biol Psychiatry, 60, 66–76.Google Scholar
Lieberman, JA, Stroup, S, McEvoy, JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.Google Scholar
Loomer, HP, Saunders, IC, Kline, NS (1957). A clinical and pharmacodynamics evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc, 8, 129–141.Google Scholar
Luengo-Fernandez, R, Leal, J, Gray, AM (2012). UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden? Eur J Neurol, 19, 149–154.Google Scholar
Macht, DJ (1920). Contributions to psychopharmacology. Johns Hopkins Hosp Bull, 31, 167.Google Scholar
McCrae, N (2006). A violent thunderstorm: cardiazol treatment in British mental hospitals. Hist Psychiatry, 17(65 Pt 1), 67–90.Google Scholar
McGovern, PE, Zhang, J, Tang, J, et al. (2004). Fermented beverages of pre- and proto-historic China. Proc Natl Acad Sci U S A, 101, 17593–17598.Google Scholar
Medical Research Council (1965). Report by the Clinical Psychiatry Committee. Clinical trial of the treatment of depressive illness. Br Med J, 1, 881–886.Google Scholar
Meltzer, HY, Alphs, L, Green, AI, et al. (2003). International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry, 60, 82–91.Google Scholar
Mindham, RHS, Howland, C, Shepherd, M (1972). Continuation therapy with tricyclic antidepressants in depressive illness. Lancet, 2, 854–855.Google Scholar
Moncrieff, J (2006). Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Med Hypotheses, 67, 517–523.Google Scholar
Moreau, JJ (1845). Du hachisch et de l’aliénation mentale: études psychologiques. Paris: Fortin Masson. English translation: Moreau JJ (1973). Hashish and Mental Illness. New York: Raven Press.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014). Bipolar disorder: assessment and management. Clinical guideline [CG185]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group (1964). Phenothiazine treatment in acute schizophrenia effectiveness. Arch Gen Psychiatry, 10, 246–261.Google Scholar
Naughton, M, Clarke, G, O’Leary, OF, Cryan, JF, Dinan, TG (2014). A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord, 156, 24–35.Google Scholar
Nelson, JC, Papakostas, GI (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry, 166, 980–991.Google Scholar
Norton, A (1979). Depression. Br Med J, 2, 429–430.Google Scholar
Nuechterlein, KH, Green, MF, Kern, RS, et al. (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry, 165, 203–213.Google Scholar
Nutt, DJ (1990). The pharmacology of human anxiety. Pharmacol Ther, 47, 233–266.CrossRefGoogle ScholarPubMed
Ohlow, MJ, Moosmann, B (2011). Phenothiazine: the seven lives of pharmacology’s first lead structure. Drug Discov Today, 16, 119–131.Google Scholar
Oxford English Dictionary Online (2018). Oxford University Press. Available at: https://en.oxforddictionaries.com/definition/psychopharmacology (last accessed 13.10.18).Google Scholar
Pearce, JMS (2002). Bromide, the first effective antiepileptic agent. J Neurol Neurosurg Psychiatry, 72, 412.Google Scholar
Physicians’ Desk Reference (1956). Methylphenidate, 11th ed. Oradell, NJ: Medical Economics, pp. 441–442.Google Scholar
Porsolt, RD, Anton, G, Blavet, N, Jalfre, M (1978). ‘Behavioural despair’ in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol, 47, 379–391.Google Scholar
Priebe, S, Badesconyi, A, Fioritti, A, et al. (2005). Reinstitutionalisation in mental health care: comparison of data on service provision from six European countries. BMJ (Clin Res Ed), 330(7483), 123–126.Google Scholar
Rapport, MM, Green, AA, Page, IH (1948). Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem, 176, 1243–1251.Google Scholar
Ray, OS (2007). About the American College of Neuropsychopharmacology. Acad Psychiatry, 31, 122–124.Google Scholar
Robinson, ES (2018). Translational new approaches to investigating mood disorders in rodents and what they may reveal about the underlying neurobiology of major depressive disorder. Philos Trans R Soc Lond B Biol Sci, 373, 20170036.Google Scholar
Schildkraut, JJ (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry, 122, 509–522.Google Scholar
Schjerning, O, Rosenzweig, M, Pottegård, A, et al. (2016). Abuse potential of pregabalin: a systematic review. CNS Drugs, 30, 9–25.Google Scholar
Schou, M, Juel-Nielsen, N, Strömgren, E, Voldby, H (1954). The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry, 17, 250–260.Google Scholar
Shorter, S (1997). A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. New York: John Wiley & Sons.Google Scholar
Siskind, D, McCartney, L, Goldschlager, R, Kisely, S (2016). Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry, 209, 385–392.Google Scholar
Sjoerdsma, AG (2008). Starting with Serotonin. Silver Spring, MD: Improbable Books, pp. 617.Google Scholar
Spedding, M, Jay, T, Costa e Silva, J, Perret, L (2005). A pathophysiological paradigm for the therapy of psychiatric disease. Nat Rev Drug Discov, 4, 467–474.Google Scholar
Stokes, JH, Sternberg, T, Schwartz, W, et al. (1944). The action of penicillin in late syphilis. JAMA, 126, 73–80.Google Scholar
Sulser, F (1984). Regulation and function of noradrenaline receptor systems in brain. Psychopharmacological aspects. Neuropharmacology, 23(2B), 255–261.CrossRefGoogle ScholarPubMed
Suttajit, S, Srisurapanont, M, Maneeton, N, Maneeton, B (2014). Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther, 8, 827–838.Google Scholar
Swazey, JP (1974). Chlorpromazine in Psychiatry: A Study of Therapeutic Innovation. Cambridge, MA: MIT Press.Google Scholar
Taylor, MJ, Freemantle, N, Geddes, JR, Bhagwagar, Z (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action, systematic review and meta-analysis. Arch Gen Psychiatry, 63, 1217–1223.Google Scholar
The Kings Fund (2015). Briefing: Mental health under pressure. Available at: www.kingsfund.org.uk/sites/default/files/field/field_publication_file/mental-health-under-pressure-nov15_0.pdf (last accessed 3.11.18).Google Scholar
Thuillier, J (1999). Ten Years That Changed the Face of Mental Illness. London: Dunitz.Google Scholar
Tillim, SJ (1952). Bromide intoxication. Am J Psychiatry, 109(3), 196–202.Google Scholar
Tjia, J, Gurwitz, JH, Briesacher, BA (2012). Challenge of changing nursing home prescribing culture. Am J Geriatr Pharmacother, 10, 37–46.Google Scholar
Tooth, GC & Newton, MP (1961). Leucotomy in England and Wales 1942–1954. Reports on Public Health and Medical Subjects No. 104. London: HMSO.Google Scholar
Tsay, CJ (2013). Julius Wagner-Jauregg and the legacy of malarial therapy for the treatment of general paresis of the insane. Yale J Biol Med, 86, 245–254.Google Scholar
Viguera, AC, Baldessarini, RJ, Hegarty, JD, van Kammen, DP, Tohen, M (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry, 54, 49–55.Google Scholar
Vogt, M (1954). The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol, 123, 451–481.Google Scholar
Weisler, RH, Nolen, WA, Neijber, A, et al.; Trial 144 Study Investigators (2011). Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry, 72, 1452–1464.Google Scholar
Windholz, G, Witherspoon, LH (1993). Sleep as a cure for schizophrenia: a historical episode. Hist Psychiatry, 4(13, Pt 1), 83–93.Google Scholar
Wolman, BB (1977). International Encyclopedia of Psychiatry, Psychology, Psychoanalysis and Neurology. New York: Aesculapius Publishers, p. 267.Google Scholar
Woolley, DW, Shaw, E (1954). A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci U S A, 40, 228–231.Google Scholar
Zajecka, JM, Stanford, AD, Memisoglu, A, Martin, WF, Pathak, S (2019). Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3). Neuropsychiatr Dis Treat, 15, 795–808.Google Scholar
Zeller, EA, Barsky, J, Berman, JR, Fouls, JR (1952). Action of isonicotinic acid hydrazide and related compounds on enzymes involved in the autonomic nervous system. J Pharmacol Exp Ther, 106, 427–432.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×